Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Liquid embolic helps to treat cerebral aneurysms

Valor Medical : 03 June, 2008  (New Product)
Neucrylate is a new technology developed to treat cerebral aneurysms which is a liquid embolic that has been developed by medical device company Valor Medical, a San Diego, California, USA.
The early results on the use of Neucrylate has been reported by Dr Charles Kerber, University of California San Diego at the American Society of Neuroradiology Conference in New Orleans, USA.

'The patients have had very positive results and to date the accumulated patient Implant times have reached 1400 days,' Dr Kerber stated.

The Implant procedure begins by placing a microcatheter into an artery in the groin and then is passed up into the brain. The Catheter is positioned in the aneurysm and Neucrylate is injected into the aneurysm. When Neucrylate comes in contact with the blood in the aneurysm it changes from a liquid to a sponge-like material. Once the Catheter is in place the treatment time is approximately one to two minutes.

Dr Sean Pakbaz, University of California San Diego, has performed all the implants to date. 'The more I use Neucrylate the more I'm impressed with how it works. Reducing the time it takes to treat an aneurysm is always a major goal when working in the brain. Implanting Neucrylate takes a lot less time than implanting coils. Neucrylate also fills the aneurysm compared to coils which only fill 30 to 40 percent of the aneurysm,' Dr Pakbaz stated.

Clark Adams, chief executive officer, said, 'Valor Medical is very excited with the early results from our clinical trials. Valor will be expanding the trial sites in Europe within a few months and we expect to begin trials in the US later this year. The company anticipates launching Neucrylate in Europe by early 2010'.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo